Zoetis, the world’s leading animal health company, announced that it will expand its portfolio of products and services for horses with the Stablelab® hand-held, point-of-care diagnostic blood test, which provides veterinarians critical information related to equine inflammation in 10 minutes.
The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), which is a major, acute-phase protein produced by the liver that rapidly and dramatically increases in response to inflammation caused by infection. By measuring SAA, veterinarians can assess the severity of infection sooner – often, before clinical symptoms start — and are able to monitor the horse’s response over the course of treatment.
“Zoetis has always been committed to providing veterinarians and horse owners with new and enhanced solutions to better predict, prevent, detect and treat disease in the animals under their care,”
said Jeannie Jeffery, Business Unit Head, U.S. Equine for Zoetis.
“The Stablelab test kit broadens our equine offerings with convenient stall-side testing for quickly and accurately detecting a reliable indicator of infection in horses. Point-of-care testing is one of the fastest-growing areas of diagnostics and this test is rapidly becoming a standard of care in equine practice.”
Jeffery added that SAA provides the most accurate biomarker of inflammation caused by infection allowing practitioners a means to monitor response to treatment over time.
Stablelab joins the Zoetis Diagnostics portfolio which features the VetScan®, Alinity (i-STAT) and other point of care diagnostic product lines. These products complement the range of equine health offerings from Zoetis and align with the company’s focus on health and wellness as part of the continuum of animal care.
Zoetis will manufacture, market and distribute the commercially available Stablelab products.